Jim Cramer says to buy shares of Danaher on the dip

The life sciences and medical technology company beat earnings estimates in the third quarter but narrowed its 2022 bioprocessing revenue growth forecast.

from Health and Science https://ift.tt/TIZ7swq
https://ift.tt/UPBAR0C
https://ift.tt/FuTQWY5